1. Home
  2. BROS vs CYTK Comparison

BROS vs CYTK Comparison

Compare BROS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dutch Bros Inc.

BROS

Dutch Bros Inc.

HOLD

Current Price

$61.91

Market Cap

8.1B

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$62.50

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BROS
CYTK
Founded
1992
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.1B
8.0B
IPO Year
2021
2004

Fundamental Metrics

Financial Performance
Metric
BROS
CYTK
Price
$61.91
$62.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
18
16
Target Price
$76.72
$82.38
AVG Volume (30 Days)
2.9M
2.2M
Earning Date
02-11-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
56.73
N/A
EPS
0.51
N/A
Revenue
$1,537,335,000.00
$87,211,000.00
Revenue This Year
$28.88
$339.72
Revenue Next Year
$25.56
$79.08
P/E Ratio
$122.84
N/A
Revenue Growth
28.93
2609.26
52 Week Low
$47.16
$29.31
52 Week High
$86.88
$70.98

Technical Indicators

Market Signals
Indicator
BROS
CYTK
Relative Strength Index (RSI) 51.20 47.75
Support Level $59.50 $60.30
Resistance Level $63.29 $65.08
Average True Range (ATR) 2.33 2.91
MACD -0.35 -0.01
Stochastic Oscillator 50.32 45.74

Price Performance

Historical Comparison
BROS
CYTK

About BROS Dutch Bros Inc.

Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies and other beverages. The company has two reportable operating segments Company-operated shops and Franchising. It derives maximum revenue from Company operated shops.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: